The Revolution in Anticlotting Agents: A Brief PrimerHenry Black talks to Jonathan Halperin about the new and more selective platelet inhibitors, the new anticoagulants, and how they may change anticlotting approaches.
Update on Aspirin and Cancer PreventionProfessor Jack Cuzick reviews the latest research on the use of aspirin for cancer prevention, as reported at the Royal Society of Medicine in London.
Should Doctors Invest in Facebook?Investors often kick themselves for not having grabbed the opportunity to invest early in Microsoft or other companies that skyrocketed. Could Facebook be the same type of opportunity?
What Would Healthcare Be Like Under 'President Romney'?The Presidential election is months away, but physicians, consumers, and politicians are speculating on changes Mitt Romney might make to our current healthcare system. Here are some possibilities.
Medscape Business of Medicine, May 2012
Medscape's Best Places to PracticeLooking for a great place to practice medicine? You've got some terrific options. We analyzed physician density, malpractice coverage, insurance competition, medical board activity, insurance mix, income taxes, and cost of living in all 50 US states and the District of Columbia and come up with a list of the best -- and the worst -- states to practice in each region.
Medscape Features Slideshows, May 2012
More Patients, More Revenue, but Less Rush. How?Doctors may think the only way to increase revenue is to add services, do more marketing, and change their practice. But there are ways to make more money by adapting what you're already doing. Here's how.
Medscape Business of Medicine, May 2012
of
Pharmacists News
– From Medscape Medical News, Reuters and more
AlertEU Okays Combination Type 2 Diabetes PillThe advisory board of the European Medicines Agency has issued a "positive opinion" for a new type 2 diabetes combination product containing linagliptin and metformin.
Lung Cancer: New Drugs, Emerging TherapiesDr. Mark Kris highlights new developments in lung cancer -- including targeted therapies for small cell carcinoma and promising immunotherapies -- to be presented at ASCO® 2012.
